Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627480 · ClinicalTrials.gov registry record · Phase 4
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
A Phase 4 study of Insomnia and Sleep, sponsored by ProofPilot.
- Active
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04627480: Active Phase 4 study of Insomnia and Sleep, sponsored by ProofPilot.
NCT04627480 is a Phase 4 study of Insomnia and Sleep that is active but no longer recruiting, run by ProofPilot. The registered enrollment target is 200 participants, above the 169-participant average among 151 other Insomnia trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04627480, a Phase 4 study of Insomnia and Sleep, is active but no longer recruiting, sponsored by ProofPilot.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device (CES) for the treatment of insomnia characterized by difficulties with sleep maintenance using a 20-minute treatment right before bedtime.
Primary Outcome
Measured by Fitbit Charge 4 connected health device work on the wrist
Conditions Studied
Interventions
- DEVICE Fisher Wallace Neurostimulation Device
Study Locations (1)
New York
- ProofPilot (Remote Virtual Trial) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-02-21 |
| Phase | Phase 4 |
What the registry record for NCT04627480 still lists
NCT04627480 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 169-participant average among 151 other Insomnia trials with a reported enrollment target (18% higher).
The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which Fisher Wallace Neurostimulation Device is the first listed.
NCT04627480 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04627480 about?
NCT04627480 is a clinical study titled "Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial". Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device (CES) for the treatment of insomnia characterized by difficulties with sleep maintenance using a 20-minute treatment right before bedtime.
What is the current status of trial NCT04627480?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-10-01. Estimated completion is 2021-02-21.
What conditions does trial NCT04627480 study?
This clinical trial studies the following conditions: Insomnia, Sleep, Insomnia Chronic.
What interventions are being tested in trial NCT04627480?
The interventions under investigation include: Fisher Wallace Neurostimulation Device (DEVICE).
Who is sponsoring clinical trial NCT04627480?
This trial is sponsored by ProofPilot, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627480 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04627480's enrollment target sits among peer trials
200 34th of 151 higher than 116 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
RECRUITING · Phase 4
-
Enhancing Hypnotic Medication Discontinuation in Primary Care
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
ACTIVE NOT RECRUITING · Phase 4
-
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI